Shipping out MEK inhibitor resistance with SHP2 inhibitors

P Torres-Ayuso, J Brognard - Cancer discovery, 2018 - AACR
RAS is one of the most frequently altered oncogenes, yet RAS-driven tumors are largely
refractory to anticancer therapies. Fedele and colleagues demonstrate that SHP2 inhibitors …
被引用次数：35 相关文章

Shipping Out MEK Inhibitor Resistance with SHP2 Inhibitors

P Torres-Ayuso, J Brognard - Cancer discovery, 2018 - pubmed.ncbi.nlm.nih.gov
RAS is one of the most frequently altered oncogenes, yet RAS-driven tumors are largely
refractory to anticancer therapies. Fedele and colleagues demonstrate that SHP2 inhibitors …

Shipping Out MEK Inhibitor Resistance with SHP2 Inhibitors.

P Torres-Ayuso, J Brognard - Cancer Discovery, 2018 - europepmc.org
RAS is one of the most frequently altered oncogenes, yet RAS-driven tumors are largely
refractory to anticancer therapies. Fedele and colleagues demonstrate that SHP2 inhibitors …